Moderna (MRNA) reported a Q4 loss Friday of $2.91 per diluted share, swinging from a profit of $0.55 a year earlier.
Analysts polled by FactSet expected a loss of $2.83.
Revenue for the quarter ended Dec. 31 was $966 million compared with $2.81 billion a year earlier.
Analysts surveyed by FactSet expected $942.8 million.
The company reiterated its 2025 revenue guidance of $1.5 billion to $2.5 billion. Analysts polled by FactSet expect $2.36 billion.
Moderna shares fell more than 5% in premarket trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。